1.31
-0.02 (-1.5%)
-0.02 (-1.5%)
Upgrade to Real-Time
Regular Market
| Volume | 270,773 |
|
|||||
| News | - | ||||||
| Day High | 1.37 | Low High |
|||||
| Day Low | 1.2627 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -1.5% | 1.31 | 12:36:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.34 | 1.2627 | 1.37 | 1.33 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 860 | 270,773 | $ 1.31 | $ 354,436 | - | 0.6902 - 4.63 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 12:36:48 | 100 | $ 1.31 | USD |
Period:
Draw Mode:
Oncternal Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 69.71M | 53.21M | 52.70M | $ - | $ - | -0.64 | -1.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 237.50k | 30.20% |
Oncternal Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.11 | 1.40 | 1.07 | 1.21 | 911,193 | 0.20 | 18.02% |
| 1 Month | 1.23 | 1.40 | 0.99 | 1.14 | 589,401 | 0.08 | 6.5% |
| 3 Months | 0.80 | 1.87 | 0.7563 | 1.36 | 1,204,989 | 0.51 | 63.75% |
| 6 Months | 2.02 | 2.03 | 0.6902 | 1.33 | 724,512 | -0.71 | -35.15% |
| 1 Year | 3.35 | 4.63 | 0.6902 | 2.16 | 661,912 | -2.04 | -60.9% |
| 3 Years | 4.30 | 10.56 | 0.6902 | 4.29 | 939,630 | -2.99 | -69.53% |
| 5 Years | 6.87 | 10.56 | 0.6902 | 4.29 | 887,110 | -5.56 | -80.93% |
Oncternal Therapeutics Description
| Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |